Ketek will eventually be severely curtailed or go off the market

February 2007

Ketek will eventually be severely curtailed or go off the market.

There's a lot of talk of a black box warning about hepatic risk.

FDA will also reconsider Ketek's indications for sinusitis and bronchitis. These less serious infections don't justify the risk.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

You'll see manufacturers market more metabolites and isomers of existing drugs to replace drugs with expiring patents
Osteoporosis whether proton pump inhibitors (omeprazole, etc) increase the risk for fractures
Osteoporosis Women are hearing that they can take a break from their oral bisphosphonate (Fosamax, etc)
Interactions misconceptions about grapefruit juice interactions
Men's Health anticholinergics (Detrol, Ditropan, etc) for urinary symptoms in men with benign prostatic hyperplasia
Cardiology Patients are asking if their meds for Parkinson's or restless legs will cause heart trouble
Cardiology Plavix and aspirin combo for at least 12 months after getting a drug-eluting coronary stent
Substance Use Disorder dextromethorphan abuse in teens
Vaccines You'll be giving more human papillomavirus, pertussis, and herpes zoster vaccines
Dermatology New evidence is helping to clear up what works for rosacea
Hormone Therapy controversy about bioidentical hormones
Infectious Diseases Ketek will eventually be severely curtailed or go off the market
Practice the significant new drugs approved in 2006